DNA

Microsoft Corporation co-founder Bill Gates has spoken about the fake polio vaccination campaign orchestrated by former U.S. President Barack Obama’s administration to locate Osama bin Laden in Pakistan. What Happened: In an interview with The Times U.K. which was published on Friday,...

Genome sequencing company Illumina Inc (NASDAQ: ILMN) has transformed its business over the years with a handful of acquisitions and new product launches. An acquisition in 2006 was one of the most important in company history and also rewarded investors along the way. What Happened: Illumina...

Novartis AG (NYSE: NVS) has struck a deal with UK-based Artios Pharma to access DNA damage response (DDR) targets that can potentially enhance its radioligand therapies. Artios is set to get $20 million upfront and up to $1.3 billion in milestones in return for the targets....

A SPAC deal announced Thursday will see a company working on a new protein sequencing on a chip go public.  The SPAC Deal: Semiconductor company Quantum-Si is going public in a SPAC merger with HighCape Capital Acquisition Corp (NASDAQ: CAPA). The deal values Quantum-Si at $925 million. An...

Some of the best performing ETFs in 2020 have been the Ark Funds, actively managed ETFs led by Cathie Wood. A long-time Tesla Inc (NASDAQ: TSLA) and technology stock bull, Wood is now betting heavily on genomic stocks. Wood On Genomics: Genomic stocks are expected to drive strong returns for the...

OG DNA Genetics recently disclosed a licensing agreement in conjunction with Green Peak Innovations, a medical cannabis producer and distributor in the Michigan market. This arrangement will concede Green Peak Innovations consent to the DNA brand and access to their genetics portfolio for use at...

"Genetics" is a word that is often tossed around in the cannabis industry. Even before the boom in legal cannabis, plant enthusiasts knew the value that gene science could add to the recreational and medical experience. For the most part, efforts in genetic research surrounding...

DNA sequencing and array-based technologies company Illumina, Inc. (NASDAQ: ILMN) pre-announced second-quarter results Thursday that represent a "big miss" versus expectations, according to Bank of America Merrill Lynch.  The Analyst Derik de Bruin downgraded Illumina from...

The bearish case for Illumina, Inc. (NASDAQ: ILMN) has come to an end for four key reasons, according to Morgan Stanley. The Analyst Analyst Steve Beuchaw upgraded Illumina from Underweight to Equal-weight with a price target lifted from $210 to $320. The Thesis Illumina stands to benefit from...

Benzinga recently had the opportunity to pick the brain of Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) CEO Douglas M. Fambrough, Ph.D. We first looked into what RNA interference is and how it's used to treat genetic diseases. We then talked products, partnerships and stock performance and...

Benzinga recently had the chance to chat with Dicerna Pharmaceuticals Inc (NASDAQ: DRNA)’s CEO Douglas M. Fambrough, Ph.D., who explained what RNA interference is and how it is used to treat genetic diseases. Beyond this theoretical explanation, the exec walked us through the company’s...

Benzinga recently had the chance to chat with Dicerna Pharmaceuticals Inc (NASDAQ: DRNA)’s CEO Douglas M. Fambrough, Ph.D., who explained what RNA interference (RNAI) is and how it is used to treat genetic diseases. Beyond this theoretical explanation, the exec elaborated on the company...

Ever heard of RNA Interference? In case you haven’t, Benzinga reached out to Dicerna Pharmaceuticals Inc (NASDAQ: DRNA)’s CEO Douglas M. Fambrough, Ph.D., and asked him to explain how it works. Silencing Genes “RNA Interference (RNAI) is a natural process. It is a biological...

In a story first reported by Nikkei and updated recently by Le Monde, Sony Corp. (NYSE: SNE) and U.S. genome sequencing equipment maker Illumina Inc. (NASDAQ: ILMN) plan to launch a human genome analysis project in October. The project will involve the study and analysis of genetic material...